Nikola Kojic, M.D. Ph.D.
Co-founder
Oryon Cell Therapies
Oryon Cell Therapies creates autologous dopaminergic neuron grafts from a patient’s own cells to replace lost neurons in Parkinson’s disease, aiming for functional integration and disease modification. The platform combines GMP‑compliant cell differentiation, rigorous quality control, and a surgical delivery system for precise brain implantation.
- Biotechnology
Updated 6 months ago
Funding
Funding rounds are not available yet.
Founders
Ole Isacson, M.D. Ph.D.
Co-founder
Product
Problem
Parkinson’s disease and many neurodegenerative disorders cause progressive loss of specific neuronal populations, leading to motor and cognitive deficits. Current treatments address symptoms but do not replace the lost neurons, resulting in limited long‑term disease modification.
Solution
Oryon Cell Therapies develops autologous neuron replacement medicines that generate patient‑specific dopaminergic neurons from the individual’s own cells. By engineering these cells to match the patient’s genetic background, the therapy aims to avoid immune rejection and integrate functionally after transplantation into the brain. The approach is intended to restore lost neural circuitry, providing a disease‑modifying effect rather than merely alleviating symptoms. Clinical‑stage biotechnology platforms are used to differentiate, mature, and quality‑control the neuronal products before surgical delivery. The company targets Parkinson’s disease initially, with a pipeline that can be extended to other neurodegenerative conditions characterized by selective neuronal loss.
Target Audience
Primary customers are neurologists and movement‑disorder specialists treating Parkinson’s disease, as well as academic and commercial research centers developing cell‑based therapies for neurodegeneration.
Features
- Autologous cell sourcing to create patient‑specific neuronal grafts, minimizing immunogenicity
- GMP‑compliant manufacturing process for scalable production of dopaminergic neurons
- Advanced differentiation protocols that yield mature, functionally active neuronal phenotypes
- Integrated quality‑control assays to ensure cell identity, purity, and safety prior to transplantation
- Surgical delivery platform designed for precise implantation into targeted brain regions